Black Majesty

Kymera Therapeutics Announces Proposed Public Offering

Retrieved on: 
Thursday, January 4, 2024
Telephone, 2nd Floor, Lexington Avenue, Sale, Research, Form, Black Majesty, Attention, Therapy, J. P. Morgan, Form S-3, Varick Street, TPD, Prospectus, Broadridge Financial Solutions, Morgan Stanley, Security (finance)

All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Kymera.

Key Points: 
  • All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Kymera.
  • In addition, Kymera intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock at the public offering price per share, less underwriting discounts and commissions.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Morgan Stanley, J.P. Morgan and TD Cowen are acting as joint lead bookrunning managers for the offering.

Scorpion Therapeutics Appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and Expands Leadership Team

Retrieved on: 
Thursday, January 4, 2024
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Atlas Venture, Massachusetts Institute of Technology, Atlas, Entrepreneurship, Culture, Food, Medicine, Princeton University, AstraZeneca, Drug development, Georgetown University, Marketing, Drug, Molecular biology, Black Majesty, Disease, Strategic management, Pediatrics, Therapy, Neoplasm, Senior, Stanford University, Brandeis University, Cancer, Business development, Doctor of Philosophy, Growth, Patient, Corporate development, Gilead Sciences, Boston, Harvard Medical School, Food and Drug Administration, Corporation, AbbVie, Pharmaceutical industry

In addition, the Company named Jeff Albers as Executive Chair and member of the Board of Directors.

Key Points: 
  • In addition, the Company named Jeff Albers as Executive Chair and member of the Board of Directors.
  • Mr. Albers currently serves as board chairman at Blueprint Medicines and board director at Kymera Therapeutics and Spyre Therapeutics.
  • Mark Chao, M.D., Ph.D., has been named Chief Medical Officer and Erica Jackson, Ph.D., has been promoted to Chief Discovery Officer.
  • Dr. Chao joins Scorpion from TenSixteen Bio, a precision therapeutics company where he served as Co-Founder and CEO.

Triveni Bio Welcomes Jeff Albers and Allison Luo to its Board of Directors

Retrieved on: 
Wednesday, December 13, 2023
Georgetown University, Food and Drug Administration, Itch, Genetics, Atlas Venture, Bristol Myers Squibb, Abbott Laboratories, Senior, Food, Triveni, Chairperson, Medicine, Probability, FDA, AbbVie, Atopic dermatitis, Gastroenterology, OrbiMed, Black Majesty, Biochemistry, Genetic linkage, Indiana University, Drug, I&I, Inflammation, Drug development, Pharmaceutical industry, Northwestern University

WALTHAM, Mass., Dec. 13, 2023 /PRNewswire/ -- Triveni Bio Inc., a biotech company pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders, today announced the appointment of Jeff Albers as Chair of the Board and Allison Luo, M.D., to the Board of Directors.

Key Points: 
  • WALTHAM, Mass., Dec. 13, 2023 /PRNewswire/ -- Triveni Bio Inc., a biotech company pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders, today announced the appointment of Jeff Albers as Chair of the Board and Allison Luo, M.D., to the Board of Directors.
  • Jeff Albers is an accomplished leader with over 25 years in the biopharmaceutical industry.
  • Jeff currently is board chair of Blueprint Medicines, and on the board of directors at Kymera Therapeutics and Spyre Therapeutics.
  • "I am honored to assume the role of Board Chair at Triveni and to work alongside this committed team," said Albers.

Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, November 2, 2023
First grade, Research, HS, AD, PD, Food, Safety, Dana–Farber Cancer Institute, Disease, Abstract, Immunology, Cutaneous T-cell lymphoma, Uveal melanoma, STAT3, International, Physician, GDF15, Webcast, Atopic dermatitis, Therapy, Investment, CTCL, Patient, Administration, Cash, Plasma, Lymphoma, Conference, IRAK4, Development, TPD, ASH, Growth, DL2, Hypotension, DL, Solar cycle 4, Arm, AACR, Thrombocytopenia, Fast Track, PTCL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, Society, SD, Hidradenitis suppurativa, MDM2, Recurrence, Blood, Peripheral T-cell lymphoma, Neutropenia, AML, Merkel-cell carcinoma, Pharmaceutical industry, Vaccine, Fine chemical, Medical device, Angela Merkel, Sanofi, Black Majesty

ET

Key Points: 
  • ET
    WATERTOWN, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today reported financial results for the third quarter ended September 30, 2023, and provided business updates on its pipeline of protein degraders.
  • Collaboration Revenues: Collaboration revenues were $4.7 million for the third quarter of 2023 compared to $9.6 million for the third quarter of 2022.
  • Net Loss: Net loss was $52.9 million for the third quarter of 2023 compared to a net loss of $43.0 million for the third quarter of 2022.
  • Cash and Cash Equivalents: As of September 30, 2023, Kymera had $435 million in cash, cash equivalents, and investments.

NextGen Healthcare Chosen by Kymera Independent Physicians to Expand Access to Critical Hematology and Oncology Care in Rural Areas

Retrieved on: 
Thursday, July 20, 2023
Practice Management, Technology, Other Health, Health, General Health, Oncology, Health Technology, Software, Networks, Internet, Mobile, Wireless, NextGen Healthcare, Physician, Cancer, Travel, Patient, Diabetes, Hematology, Nursing, Black Majesty

NextGen Healthcare, Inc. (Nasdaq: NXGN), a leading provider of innovative, cloud-based healthcare technology solutions, today announced Kymera Independent Physicians multi-specialty group selected NextGen® Enterprise EHR – a powerful, all-encompassing electronic health record to expand access to care, while increasing clinical productivity, enriching patient experience, and ensuring healthy financial outcomes.

Key Points: 
  • NextGen Healthcare, Inc. (Nasdaq: NXGN), a leading provider of innovative, cloud-based healthcare technology solutions, today announced Kymera Independent Physicians multi-specialty group selected NextGen® Enterprise EHR – a powerful, all-encompassing electronic health record to expand access to care, while increasing clinical productivity, enriching patient experience, and ensuring healthy financial outcomes.
  • Kymera is also using NextGen® Enterprise Practice Management (PM) software to automate routine billing and administrative tasks 24/7 with personalization.
  • “Kymera provides critical access to advanced treatments for patients in highly underserved areas,” said Srinivas (Sri) Velamoor , chief growth and strategy officer and executive vice president at NextGen Healthcare.
  • “To simplify healthcare programs for our patients, we strive to have specialists who treat any condition, reducing extensive travel.

Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials

Retrieved on: 
Wednesday, June 14, 2023
STAT3, Plasmablastic lymphoma, Follicular lymphoma, IRAK4, DLBCL, Relapse, ICML, Immunomodulatory imide drug, Aes, Lymphoma, TPD, Biomarker, B-cell lymphoma, PBMC, Leukemia, International Conference on Afghanistan, London (2010), Patient, Plasma, MYD88, Cancer, ABC, Poster, Toxicity, Infrared spectroscopy correlation table, Therapy, Conference, Safety, Bone marrow, Vaccine, Pharmaceutical industry, Engineered wood, Medical imaging, Aeolus, Black Majesty

WATERTOWN, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today shared new data demonstrating that its oncology programs KT-333 and KT-413 continue to demonstrate robust dose-dependent target knockdown in ongoing Phase 1a dose escalation clinical trials, with no dose limiting toxicities (DLTs) observed. The KT-333 clinical data will be presented in a poster at the International Conference on Malignant Lymphoma (ICML) on June 16, 2023, in Lugano, Switzerland.

Key Points: 
  • The KT-333 clinical data will be presented in a poster at the International Conference on Malignant Lymphoma (ICML) on June 16, 2023, in Lugano, Switzerland.
  • “We are proud and excited to be the first company to have shown clinical translation of our degraders’ profiles across three programs and across multiple diseases and indications.
  • Data reported from the 3 completed dose levels (DL1-3) found:
    Plasma exposure increased with dose, reaching levels close to those predicted to be efficacious.
  • KT-413 achieved dose-dependent degradation of up to 70% IRAK4 and 96-100% Ikaros and Aiolos in PBMC after a single dose.

Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413

Retrieved on: 
Friday, June 9, 2023
STAT3, Peripheral T-cell lymphoma, PD, Cutaneous T-cell lymphoma, Follicular lymphoma, DLBCL, Relapse, ICML, Immunomodulatory imide drug, Lymphoma, Pharmacokinetics, Constipation, TPD, DL2, Abdominal pain, B-cell lymphoma, PBMC, Leukemia, Dizziness, Patient, International Conference on Machine Learning, Plasma, MYD88, Cancer, ABC, Nausea, Toxicity, Infrared spectroscopy correlation table, Therapy, Conference, Safety, Fatigue, Bone marrow, Vaccine, Pharmaceutical industry, Television, Risk management, Medical imaging, IRAK4, Black Majesty, Fever

WATERTOWN, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced new data demonstrating that its oncology programs KT-333 and KT-413 continue to demonstrate substantial target knockdown in ongoing Phase 1a dose escalation clinical trials, with no dose limiting toxicities (DLTs) observed. The data were shared in the online abstract book of the International Conference on Malignant Lymphoma (ICML), taking place from June 13-17, 2023, in Lugano, Switzerland, and reflect a data cut-off date of February 3, 2023. On June 14, a KT-333 poster will be released at ICML and presented on June 16. Kymera will share updated results from both programs in conjunction with the poster release on June 14.

Key Points: 
  • Kymera will share updated results from both programs in conjunction with the poster release on June 14.
  • KT-333 is designed as a potent degrader of STAT3, a transcriptional regulator that has been linked to numerous cancers as well as to inflammatory and autoimmune diseases.
  • As previously announced, Kymera intends to present data evaluating anti-tumor activity in the target patient population later this year.
  • As previously announced, Kymera intends to present data evaluating anti-tumor activity in the target patient population later this year.

Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium

Retrieved on: 
Thursday, May 18, 2023
PK, Human, PD, Toll-like receptor, Journal of the European Academy of Dermatology and Venereology, Atopic dermatitis, TPD, Inflammation, HS, European Academy of Allergy and Clinical Immunology, Patient, Hidradenitis suppurativa, Blood, Sanofi, AD, Therapy, Receptor (biochemistry), Skin, Safety, Pharmaceutical industry, Vaccine, IRAK4, Dermatology, Black Majesty, Venereology

WATERTOWN, Mass., May 18, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today presented positive Phase 1 clinical data from its lead program, KT-474 (SAR444656), a potent, highly selective, orally bioavailable IRAK4 degrader. The Company delivered an oral presentation at the European Academy of Dermatology and Venereology (EADV) Symposium, taking place from May 18-20, 2023, in Seville, Spain.

Key Points: 
  • The Company delivered an oral presentation at the European Academy of Dermatology and Venereology (EADV) Symposium, taking place from May 18-20, 2023, in Seville, Spain.
  • IRAK4 is a key protein involved in inflammation mediated by the activation of toll-like receptors (TLRs) and IL-1 receptors (IL-1Rs).
  • Aberrant activation of these pathways is the underlying cause of multiple immune-inflammatory conditions.
  • “The KT-474 Phase 1 trial was a substantial accomplishment for Kymera, showcasing the high fidelity of PK/PD and safety translation from preclinical species to humans for our heterobifunctional degrader platform.

X-Chem and Kymera Expand Existing Partnership

Retrieved on: 
Tuesday, January 31, 2023
Technology, Biotechnology, Chemicals, Plastics, Health, Manufacturing, Other Health, Pharmaceutical, Artificial Intelligence, Other Science, Other Technology, Research, Genetics, Science, Clinical Trials, Chem, DEL, Partnership, Pharmaceutical industry, Black Majesty

X-Chem , the leading provider of innovative solutions in early-stage drug discovery, today announced the expansion of its collaboration with Kymera Therapeutics, Inc. (NASDAQ: KYMR).

Key Points: 
  • X-Chem , the leading provider of innovative solutions in early-stage drug discovery, today announced the expansion of its collaboration with Kymera Therapeutics, Inc. (NASDAQ: KYMR).
  • With the expanded agreement, X-Chem will serve as the primary provider of DNA-encoded library (DEL)-based screening services to Kymera — with X-Chem applying its world-leading DEL platform to support Kymera’s discovery of first- and best-in-class protein degraders.
  • The expanded partnership comprises 12 targets and grants Kymera exclusive rights to compounds discovered within the collaboration.
  • We are delighted to be able to work more closely with Kymera and help them discover more compounds that positively impact patients.”

Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company

Retrieved on: 
Tuesday, January 10, 2023
IND, Degenerative disease, T-cell lymphoma, Blood, Plasma, MDM2, Lymphatic system, Sanofi, Entrepreneurship, Mass spectrometry, Cancer, TPD, Therapy, AML, Acute myeloid leukemia, Leukemia, Safety, SAD, Biomarker, FDA, PD, HS, Inflammation, AD, Skin, Toxic leukoencephalopathy, Conference, IV, Patient, Apoptosis, Immunomodulatory imide drug, Cycle, Atopic dermatitis, MYD88, Research, STAT3, MAD, Hidradenitis suppurativa, Human, Investment, Doctor of Philosophy, DLBCL, Follicular lymphoma, Fine chemical, Pharmaceutical industry, Vaccine, IRAK4, Black Majesty, PBMC

WATERTOWN, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced its research, development and corporate goals for 2023.

Key Points: 
  • WATERTOWN, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced its research, development and corporate goals for 2023.
  • Initial Phase 2 clinical trials of KT-474 will investigate its potential in HS and AD, with the first study initiating in 2023.
  • In December 2022 Kymera announced that Dose Level (DL) 1 had been completed with a total of 4 patients enrolled.
  • Nello Mainolfi, PhD, Co-Founder, President and CEO of Kymera, will provide an overview of the Company’s progress and 2023 goals.